Thin Disclosure but "Bulletproof" Protection: How a Salt Form Patent was Upheld in China Despite Minimal Data
2026年1月8日In China, innovative drug companies typically rely on their initial composition of matter patents to block out competitors. Other “follow-on” IP, such as those directed towards formulations, polymorphs, and salt forms, are often regarded as less likely to survive invalidation challenges, especially in China where the standard of “person skilled in the art” is so […]
閱讀更多 >